Romosozumab-aqqg

Brand names: Evenity · Active ingredient: Romosozumab

In short: EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. The anabolic effect o

Forms & strengthsInjection: 105 mg/1.17 mL clear to opalescent, colorless to light yellow solution in a single-use prefilled syringe. A full dose of EVENITY requires two single-use prefilled syringes.
LabelAmgen, Inc
Label updatedAug 03, 2026

What is Romosozumab-aqqg used for?

EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

The anabolic effect of EVENITY wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered .

âš  Boxed warning (FDA's strongest warning)

EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death . EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued.

Romosozumab-aqqg dosage

Two separate syringes (and two separate subcutaneous injections) are needed to administer the total dose of 210 mg of EVENITY. Inject two 105 mg/1.17 mL prefilled syringes, one after the other.

EVENITY should be administered by a healthcare provider.

The recommended dose of EVENITY is 210 mg administered subcutaneously in the abdomen, thigh or upper arm. Administer EVENITY once every month.

The treatment duration for EVENITY is 12 monthly doses.

Patients should be adequately supplemented with calcium and vitamin D during treatment with EVENITY .

If the EVENITY dose is missed, administer as soon as it can be rescheduled. Thereafter, EVENITY can be scheduled every month from the date of the last dose.

Administration instructions: Prefilled syringe with automatic needle guard:

Step 1: Prior to Administration:

Remove two syringes from the carton.

Visually inspect EVENITY for particles and discoloration prior to administration. EVENITY is a clear to opalescent, colorless to light yellow solution. Do not use if the solution is cloudy or discolored or contains particles.

Do not use the syringe if

any part appears cracked or broken

the gray needle cap is missing or not securely attached

the expiration date printed on the label has passed

the syringe has been dropped on a hard surface

Always hold the syringe by the syringe body to remove the syringe from the tray. See Figure A.

Do not grasp the plunger rod.

Do not grasp the gray needle cap.

Do not remove the gray needle cap until you are ready to inject.

Allow EVENITY to sit at room temperature for at least 30 minutes before injecting. Do not warm in any other way .

Figure A

Step 2: Select the Injection Site and Prepare the Syringe

Prepare and clean two injection sites, one for each of the two injections. See Figure B.

Figure B

The recommended subcutaneous injection sites include:

The thigh

Abdomen, except for a two-inch area right around the navel

Outer area of upper arm

Clean the injection sites with alcohol wipes. Let the skin dry.

Choose a different site each time you give an injection. If you want to use the same injection site, make sure it is not the same spot on the injection site you used for a previous injection.

Do not inject into areas where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks.

Choose the first syringe. Pull the gray needle cap straight off and away from your body when you are ready to inject. See Figure C.

Figure C

Do not put the gray needle cap back onto the syringe.

Do not leave the cap off for more than 5 minutes as this can dry out the solution.

The prefilled syringe may contain air bubbles. Do not try to push air bubbles out as it is normal to see air bubbles. …

How to take Romosozumab-aqqg — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Major Adverse Cardiac Events

Advise patients to seek immediate medical attention if they experience signs or symptoms of a myocardial infarction or stroke .

Hypersensitivity Reactions

Advise patients to seek immediate medical attention if they experience signs or symptoms of a hypersensitivity reaction including angioedema, erythema multiforme, dermatitis, rash, and urticaria .

Calcium and Vitamin D Supplements to Prevent Hypocalcemia

Advise patients to take calcium and vitamin D supplements daily to reduce the risk of hypocalcemia. Advise patients to seek immediate medical attention for symptoms of hypocalcemia [see Dosage and Administration (2.1), Warnings and Precautions (5.3) and Adverse Reactions (6.1)].

Osteonecrosis of the Jaw

Advise patients to practice good oral hygiene during treatment with EVENITY and tell their dentist that they are receiving EVENITY before having dental work. .

Atypical Femoral Fracture

Advise patients to report signs and symptoms that could be consistent with impending atypical femoral fracture including new or unusual thigh, hip, or groin pain .

Warnings & precautions

Do not take this medicine if: EVENITY is contraindicated in patients with:

Hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENITY [see Warnings and Precautions (5.3), Adverse Reactions (6.1) and Use in Specific Populations (8.7)].

A history of systemic hypersensitivity to romosozumab-aqqg or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria .

In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENITY compared to those treated with alendronate .

EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued.

Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENITY-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENITY .

Hypocalcemia has occurred in patients receiving EVENITY. Correct hypocalcemia prior to initiating EVENITY . Monitor patients for signs and symptoms of hypocalcemia. Patients should be adequately supplemented with calcium and vitamin D while on EVENITY . …

Romosozumab-aqqg side effects

The following adverse reactions are discussed in greater detail in other sections of the label:

Major adverse cardiac events

Hypersensitivity

Hypocalcemia

Osteonecrosis of the Jaw

Atypical Subtrochanteric and Diaphyseal Femoral Fractures

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of EVENITY for the treatment of postmenopausal osteoporosis was evaluated in a multicenter, randomized, double-blind, placebo-controlled study (Study 1, NCT01575834) of 7180 postmenopausal women aged 55 to 90 years (mean age of 71 years). A total of 3581 and 3576 women received at least one dose of EVENITY and placebo, respectively, administered once every month during the 12-month double-blind study period. Women received at least 500 mg calcium and 600 international units of vitamin D supplementation daily and 77% received a loading dose of 50,000 to 60,000 international units of vitamin D within one week of randomization (if serum 25-hydroxyvitamin D concentrations were 40 ng/mL or less). …

About this medicine

Romosozumab-aqqg is a humanized monoclonal antibody (IgG2) produced in a mammalian cell line (Chinese Hamster Ovary) by recombinant DNA technology that binds to and inhibits sclerostin. Romosozumab-aqqg has an approximate molecular weight of 149 kDa.

EVENITY (romosozumab-aqqg) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous injection in a single-use prefilled syringe.

Two 105 mg/1.17 mL single-use prefilled syringes are required to administer the recommended 210 mg dose of EVENITY . Each single-use prefilled syringe delivers 1.17 mL of solution containing 105 mg of romosozumab-aqqg, acetate (3.8 mg), calcium (0.61 mg), polysorbate 20 (0.07 mg) and sucrose (70 mg) in Water for Injection, USP, and sodium hydroxide to a pH of 5.2.

How it works: EVENITY inhibits the action of sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 471baba2-7154-4488-9891-0db2f46791e7. Read the full official label on DailyMed.

Related medicines

Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone